Results 51 to 60 of about 701,449 (267)

Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. [PDF]

PLoS ONE, 2012
Inhibitory receptors mediate CD8 T-cell hyporesponsiveness against cancer and infectious diseases. PD-1 and CTLA-4 have been extensively studied, and blocking antibodies have already shown clinical benefit for cancer patients.
Lukas Baitsch, Amandine Legat, Leticia Barba, Silvia A Fuertes Marraco, Jean-Paul Rivals, Petra Baumgaertner, Céline Christiansen-Jucht, Hanifa Bouzourene, Donata Rimoldi, Hanspeter Pircher, Nathalie Rufer, Maurice Matter, Olivier Michielin, Daniel E Speiser   +13 more
doaj   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

FEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg, Martine Hjeltnes, Josephine Krieger, Joshua E. Elias, Maria Stensland, Kristian Holm, Xiaojun Jiang, Chuki Khangsar, Tuula A. Nyman, Arthur Kaser, Johannes R. Hov, Tom H. Karlsen, Nicole C. Kaneider, Frode L. Jahnsen, Georg Schneditz   +14 more
wiley   +1 more source

Modular delivery of co-stimulatory signals through a PD-1-based immunoswitch receptor improves the functionality of Hepatitis B Virus-specific engineered T cells

Frontiers in Immunology
In chronic hepatitis B virus infection (cHBV), T-cell responses are skewed. This prevents the elimination of HBV-infected hepatocytes, contributes to hepatocellular carcinoma development, and limits the efficacy of T-cell therapies.
Luis Felipe Olguín-Contreras, Johanna Heep, Lisa Schiller, Eva Loffredo-Verde, Marvin M. Festag, Kai Metzger, Stephanie Färber, Merve Gültan, Margaret Tulessin, Susanne Wilde, Karin Wisskirchen, Karin Wisskirchen, Elfriede Noessner, Ulrike Protzer, Ulrike Protzer   +14 more
doaj   +1 more source

Functional Development of the T Cell Receptor for Antigen [PDF]

, 2010
For over three decades now, the T cell receptor (TCR) for antigen has not ceased to challenge the imaginations of cellular and molecular immunologists alike. T cell antigen recognition transcends every aspect of adaptive immunity: it shapes the T cell repertoire in the thymus and directs T cell-mediated effector functions in the periphery, where it is ...
Peter J R, Ebert, Qi-Jing, Li, Johannes B, Huppa, Mark M, Davis   +3 more
openaire   +2 more sources

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment

Frontiers in Immunology
Adoptive T cell therapy has transformed cancer treatment, with chimeric antigen receptor (CAR) T cell therapy demonstrating remarkable clinical success in hematological malignancies.
Riley Rane, Riley Rane, Fengqiao Li, Fengqiao Li, Alexis Williams, Alexis Williams, Avaneesh Jayadev, Avaneesh Jayadev, Nhan L. Tran, Nhan L. Tran, Jeffrey A. Winkles, Jeffrey A. Winkles, Gloria B. Kim, Gloria B. Kim   +13 more
doaj   +1 more source

Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy.

PLoS ONE, 2014
While much of cancer immunology research has focused on anti-tumor immunity both systemically and within the tumor microenvironment, little is known about the impact of pre-existing malignancy on pathogen-specific immune responses.
Rohit Mittal, Maylene Wagener, Elise R Breed, Zhe Liang, Benyam P Yoseph, Eileen M Burd, Alton B Farris, Craig M Coopersmith, Mandy L Ford   +8 more
doaj   +1 more source

Chimeric Antigen Receptor T-Cell Therapy [PDF]

Journal of the National Comprehensive Cancer Network, 2018
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases.
Ndiya, Ogba, Nicole M, Arwood, Nancy L, Bartlett, Mara, Bloom, Patrick, Brown, Christine, Brown, Elizabeth Lihua, Budde, Robert, Carlson, Stephanie, Farnia, Terry J, Fry, Morgan, Garber, Rebecca A, Gardner, Lauren, Gurschick, Patricia, Kropf, Jeff J, Reitan, Craig, Sauter, Bijal, Shah, Elizabeth J, Shpall, Steven T, Rosen   +18 more
openaire   +2 more sources

Peripheral lysosomes recruit PLEKHG3 to focal adhesions and restrain protrusion dynamics

FEBS Letters, EarlyView.
Proximity‐dependent labeling at the LAMTOR complex revealed the Rho GEF PLEKHG3 as a lysosome‐proximal protein directing the study toward the influence of lysosome positioning on actin dynamics and cell motility. We show that PLEKHG3 colocalizes with lysosomes at focal adhesion sites and observe that forced peripheral dispersion of lysosomes hinders ...
Rainer Ettelt, Ana‐Maria Sandru, Georg Vucak, Sebastian Didusch, Biljana Riemelmoser, Karin Ehrenreiter, Markus Hartl, Lukas A. Huber, Manuela Baccarini   +8 more
wiley   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, EarlyView.
Jonathan Cunningham
wiley   +1 more source